Hair loss breakthrough? new cell injection trial begins
NCT ID NCT07618195
First seen Jun 15, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment called EPI-001 for androgenetic alopecia (male/female pattern baldness). EPI-001 is made from a patient's own hair follicle cells and injected into the scalp. The study will enroll 42 adults to check safety and see if it can regrow hair, comparing it to a placebo over up to 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chung-Ang University Hospital
RECRUITINGSeoul, Seoul, 06973, South Korea
Contact
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EPI-001 (a cell-based injection made from the patient's own hair follicle cells)
What this could lead to
If it works, this could point toward a new treatment that regrows hair in people with pattern baldness.
What could go wrong
This is a very early, small trial (42 people) focused on safety. The treatment may not regrow hair, and side effects from the injections are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.